Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study

NCT04252612 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Poor accrual

Conditions

Cutaneous Squamous Cell Carcinoma

Interventions

DRUG: Pramlintide

Sponsor

H. Lee Moffitt Cancer Center and Research Institute